Howard W. Robin net worth and biography

Howard Robin Biography and Net Worth

Howard W. Robin is President, Chief Executive Officer, Director of the Company. Mr. Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a director. From 1991 to 2001, Mr. Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc. (Berlex), a pharmaceutical products company that is a subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer of Berlex. From 1984 to 1987, Mr. Robin was Director of Business Planning and Development at Berlex. He was a Senior Associate with Arthur Andersen & Co. prior to joining Berlex. Mr. Robin serves as a director of the Biotechnology Industry Organization, the world’s largest biotechnology industry trade organization, and also serves as a director of BayBio, a non-profit trade association serving the Northern California life sciences community. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University in 1974.

What is Howard W. Robin's net worth?

The estimated net worth of Howard W. Robin is at least $3.03 million as of November 16th, 2022. Mr. Robin owns 979,793 shares of Nektar Therapeutics stock worth more than $3,027,560 as of February 5th. This net worth estimate does not reflect any other assets that Mr. Robin may own. Learn More about Howard W. Robin's net worth.

What is Howard W. Robin's salary?

As the CEO of Nektar Therapeutics, Mr. Robin earned a total compensation package of $11,153,616.00 in 2021. Mr. Robin earned a salary of $1,053,000.00, stock awards of $5,691,794.00, options awards of $3,326,492.00, non-equity compensation of $1,000,350.00, and other compensation of $81,980.00. Learn More on Howard W. Robin's salary.

How do I contact Howard W. Robin?

The corporate mailing address for Mr. Robin and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected] Learn More on Howard W. Robin's contact information.

Has Howard W. Robin been buying or selling shares of Nektar Therapeutics?

Howard W. Robin has not been actively trading shares of Nektar Therapeutics within the last three months. Most recently, Howard W. Robin sold 38,014 shares of the business's stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $3.57, for a transaction totalling $135,709.98. Following the completion of the sale, the chief executive officer now directly owns 979,793 shares of the company's stock, valued at $3,497,861.01. Learn More on Howard W. Robin's trading history.

Who are Nektar Therapeutics' active insiders?

Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.

Are insiders buying or selling shares of Nektar Therapeutics?

During the last year, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 314,077 shares worth more than $1,549,090.27. The most recent insider tranaction occured on November, 16th when insider Jonathan Zalevsky sold 13,460 shares worth more than $48,052.20. Insiders at Nektar Therapeutics own 3.4% of the company. Learn More about insider trades at Nektar Therapeutics.

Information on this page was last updated on 11/16/2022.

Howard W. Robin Insider Trading History at Nektar Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2022Sell38,014$3.57$135,709.98979,793View SEC Filing Icon  
8/16/2022Sell13,759$4.76$65,492.841,017,807View SEC Filing Icon  
5/16/2022Sell36,529$3.95$144,289.55620,941View SEC Filing Icon  
2/16/2022Sell12,480$10.95$136,656.00View SEC Filing Icon  
8/16/2021Sell11,515$13.83$159,252.45424,123View SEC Filing Icon  
5/17/2021Sell11,560$18.30$211,548.00435,638View SEC Filing Icon  
2/3/2021Sell150,000$19.72$2,958,000.00608,693View SEC Filing Icon  
8/17/2020Sell11,885$19.67$233,777.95364,018View SEC Filing Icon  
2/18/2020Sell8,448$22.35$188,812.80384,871View SEC Filing Icon  
11/18/2019Sell13,556$17.97$243,601.32299,219View SEC Filing Icon  
10/16/2019Sell33,334$17.48$582,678.32346,108View SEC Filing Icon  
8/16/2019Sell12,551$18.15$227,800.65282,775View SEC Filing Icon  
7/24/2019Sell33,334$32.11$1,070,354.74328,659View SEC Filing Icon  
5/23/2019Sell100,000$33.00$3,300,000.00328,659View SEC Filing Icon  
5/21/2019Sell33,333$32.93$1,097,655.69328,659View SEC Filing Icon  
5/16/2019Sell13,383$31.37$419,824.71295,326View SEC Filing Icon  
2/21/2019Sell108,882$42.19$4,593,731.58350,924View SEC Filing Icon  
2/19/2019Sell42,215$42.33$1,786,960.95350,924View SEC Filing Icon  
11/16/2018Sell15,326$38.25$586,219.50249,141View SEC Filing Icon  
6/27/2018Sell130,000$49.52$6,437,600.00267,690View SEC Filing Icon  
6/25/2018Sell43,334$51.82$2,245,567.88267,690View SEC Filing Icon  
5/16/2018Sell12,791$83.39$1,066,641.49224,356View SEC Filing Icon  
5/3/2018Sell130,000$84.05$10,926,500.00280,481View SEC Filing Icon  
5/1/2018Sell43,334$83.65$3,624,889.10280,481View SEC Filing Icon  
2/16/2018Sell12,788$82.94$1,060,636.72237,147View SEC Filing Icon  
1/22/2018Sell83,333$75.82$6,318,308.06333,268View SEC Filing Icon  
12/13/2017Sell83,333$55.69$4,640,814.77272,768View SEC Filing Icon  
11/1/2017Sell83,334$23.57$1,964,182.38235,838View SEC Filing Icon  
10/9/2017Sell83,333$24.20$2,016,658.60View SEC Filing Icon  
9/6/2017Sell83,333$21.54$1,794,992.82235,837View SEC Filing Icon  
8/16/2017Sell91,714$19.26$1,766,411.64152,504View SEC Filing Icon  
5/16/2017Sell8,388$19.55$163,985.40160,884View SEC Filing Icon  
2/16/2017Sell8,636$13.14$113,477.04169,272View SEC Filing Icon  
2/8/2017Sell87,500$13.04$1,141,000.00265,408View SEC Filing Icon  
1/17/2017Sell87,500$12.35$1,080,625.00265,408View SEC Filing Icon  
11/17/2016Sell93,458$13.88$1,297,197.04122,908View SEC Filing Icon  
10/4/2016Sell87,500$17.06$1,492,750.00View SEC Filing Icon  
9/1/2016Sell87,500$17.83$1,560,125.00View SEC Filing Icon  
8/16/2016Sell11,817$17.56$207,506.52View SEC Filing Icon  
5/17/2016Sell2,170$13.58$29,468.6019,103View SEC Filing Icon  
2/17/2016Sell2,147$11.92$25,592.2413,478View SEC Filing Icon  
2/10/2016Sell66,666$11.49$765,992.3410,000View SEC Filing Icon  
1/19/2016Sell66,667$14.12$941,338.0410,000View SEC Filing Icon  
12/3/2015Sell125,001$15.87$1,983,765.8710,000View SEC Filing Icon  
11/11/2015Sell125,000$13.52$1,690,000.0010,000View SEC Filing Icon  
10/6/2015Sell125,000$10.99$1,373,750.0010,000View SEC Filing Icon  
9/23/2015Sell124,999$13.04$1,629,986.9610,000View SEC Filing Icon  
8/13/2015Sell58,333$10.89$635,246.37View SEC Filing Icon  
7/14/2015Sell58,334$11.78$687,174.52View SEC Filing Icon  
12/1/2014Sell350,000$17.01$5,953,500.00View SEC Filing Icon  
11/25/2014Sell600,000$15.25$9,150,000.00View SEC Filing Icon  
11/24/2014Sell132,800$15.02$1,994,656.00View SEC Filing Icon  
See Full Table

Howard W. Robin Buying and Selling Activity at Nektar Therapeutics

This chart shows Howard W Robin's buying and selling at Nektar Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nektar Therapeutics Company Overview

Nektar Therapeutics logo
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Read More

Today's Range

Now: $3.09
Low: $2.89
High: $3.15

50 Day Range

MA: $2.55
Low: $2.03
High: $3.10

2 Week Range

Now: $3.09
Low: $1.99
High: $11.59


1,509,001 shs

Average Volume

1,310,673 shs

Market Capitalization

$580.77 million

P/E Ratio


Dividend Yield